Purpose BRCA gene mutations and elevated serum estradiol (E 2 ) are well-known risk factors for breast cancer. The aim of this study was to investigate the association between BRCA gene mutations and serum E 2 level. Methods We measured baseline (menstrual cycle day 2-3) E 2 levels of 96 women with breast cancer who underwent BRCA testing. Results The mean age, parity, and age at menarche did not differ between women with and without BRCA1/2 mutations. Basal serum E 2 level was significantly higher in women with BRCA2 mutations compared to women with BRCA1 mutations or without BRCA mutations (71.7 ± 41.6 vs. 45.5 ± 20.7 vs. 38.5 ± 12.6 pg/ml in BRCA2 mutation carriers, BRCA1 mutation carriers, and non-carriers, respectively, p value = 0.03). Women with BRCA2 mutations had 3.1 times as great risk for high basal E 2 level ([48 pg/ml) as women without BRCA mutations after adjusting for age and BMI (95 % confidence interval: 1.3, 7.6). BRCA mutation carriers with high serum E 2 level were significantly younger than the carriers with low serum E 2 level (31.4 ± 3.1 vs. 34.7 ± 4.9 years, p = 0.04). Conclusions In this pilot study, we found an association between high basal serum E 2 levels and BRCA2 mutations. Our results suggest that increased production of E 2 may have a role in the pathogenesis of BRCA2-mutation-related breast cancer.
Introduction
A large number of germline BRCA gene mutations are associated with breast cancer development [1] . The cumulative risk of breast carcinoma in carriers of BRCA mutations ranges from 45 to 84 % by age 70 [2, 3] . BRCA genes are members of the ATM/ATR-mediated DNA double-strand break (DSB) repair pathway. Germline mutations in one allele and subsequent dysfunction of the intact allele eventually lead to accumulation of impaired DSB repair which in turn results in mutagenesis and carcinogenesis [4] . This mechanism of action, however, does not sufficiently explain why BRCA-associated tumors predominantly occur in estrogen-responsive tissues, such as the breast and ovary [5] .
Several studies have shown a possible role of estrogen action, another well-known risk factor for breast carcinogenesis, as a risk modifier in BRCA-associated breast cancer. Prophylactic oophorectomy decreases the risk of breast carcinoma in BRCA mutation carriers [6] [7] [8] , likely due to the profound drop in circulating estrogen after surgery. Tamoxifen decreases the risk of a secondary breast malignancy in BRCA mutation carriers [9, 10] . However, despite these clinical studies, the role of estrogen action on BRCA-mutation-associated breast cancer risk modification is not as clear as in sporadic breast cancer.
There is also biologic evidence of interactions between BRCA proteins and estrogen action. First, normal BRCA1 expression can be induced by estrogen exposure in experimental models [11] . Second, the wild-type BRCA1 gene negatively regulates aromatase expression in a human granulosa cell line [12] , likely suppressing estrogen production. Finally, although the relationship between the BRCA2 gene function and estrogen metabolism has not been investigated as extensively as it has been with BRCA1, a link was reported between estrogen action and BRCA2 protein function in breast cancer cell lines [13] .
Based on the foregoing, we hypothesized an interaction among serum estrogen levels, BRCA mutation status and breast carcinogenesis. To probe this relationship, we evaluated the baseline serum estradiol (E 2 )-most potent biologic form of estrogen-levels in breast cancer patients in relationship to BRCA gene mutations. Because serum E 2 levels vary throughout the cycle in premenopausal women, we used menstrual cycle day 2/3 measurements which standardizes the assessment of baseline estrogen output [14] .
Methods
We performed a secondary analysis of the prospective COST-LESS (Controlled Ovarian Stimulation Treatment with Letrozole Supplementation Study) study, details of which were published elsewhere [5] . One hundred consecutive premenopausal patients with breast cancer, age 24-44, who were referred for fertility reservation and underwent BRCA testing were included. The exclusion criteria were as follows: evidence of peri-menopause or menopause, medications affecting basal estrogen levels such as the oral contraceptive use within the last 4 weeks, history of ovarian surgery, and prior chemotherapy or radiation therapy.
Continuous data (presented as mean ± standard deviation) were analyzed by ANOVA, t test, or Kruskal-Wallis test as appropriate. Categorical data were analyzed using v 2 or Fisher's exact tests as appropriate. A two-tailed P \ 0.05 was considered statistically significant. To correct for the multiple comparisons, a Bonferroni adjustment was used. Linear regression analysis was used to calculate the risk ratios for high basal E 2 levels in groups of patients stratified by BRCA gene mutation status. Statistical analysis was performed with the SAS 9.2 for Windows package (SAS, Cary, NC).
Results

Patients characteristics
Of the one hundred women with recent diagnosis of breast cancer who underwent BRCA testing, four who recently used oral contraceptive pills were excluded leaving data from 96 for final analysis. The mean age of the study population was 35.6 ± 4.8 years (range 24-44 years). Of those 96 women, 67 (70 %) were negative for BRCA mutations, and 29 (30 %) carried BRCA mutations. Among 29 BRCA mutation carriers, 21 (72 %) patients had BRCA1 mutations and 8 (28 %) had BRCA2 mutations. The mean age, parity, BMI, and age at menarche were not different among women with BRCA1, BRCA2 mutations, and without BRCA gene mutations ( Table 1 Serum E 2 levels in relationship to BRCA gene mutations Basal serum E 2 levels, which were analyzed from blood drawn on menstrual cycle day 2/3, were significantly Fig. 1 ). The association between basal E 2 level and BRCA2 gene mutation status remained significant after adjusting the analysis for age and BMI. Basal follicle-stimulating hormone levels were not different by BRCA gene mutation status, indicating that the difference in E 2 levels was not related to diminished ovarian reserve (data not shown). When we dichotomized basal E 2 levels with a cutoff point of 48 pg/ml, which is the 75th percentile E 2 value for our study population (high; E 2 [ 48 pg/ml and low; E 2 B 48 pg/ml), the risk for high basal E 2 level for patients with BRCA2 gene mutations was 3.1 times as great as that of patients without BRCA gene mutations after adjusting the analysis for age and BMI (95 % confidence interval: 1.3, 7.6, Table 2 ).
Patient characteristics by serum E 2 level
Analysis of BRCA mutation carriers by serum E 2 level (high; E 2 [ 48 pg/ml vs. low; E 2 B 48 pg/ml) revealed that the carriers with high serum E 2 levels were significantly younger than the carriers with low serum E 2 level and non-carriers (Table 3) . The age at menarche was significantly later in carriers with high serum E 2 levels compared to those with low serum E 2 (p = 0.01, Table 3 ). However, the mean age and age at menarche were not different by serum E 2 level among non-carriers. Paradoxically, we would expect higher baseline E 2 levels in older women as higher E 2 levels are associated with lower ovarian reserve due to accelerated follicle growth in the aging ovary [15] . This finding strengthens the association between BRCA status and high estrogen production and excludes the possibility that the difference in E 2 levels is related to differences in ovarian reserve.
Discussion
To our knowledge, this is the first report to demonstrate a possible relationship between serum E 2 levels and BRCA gene mutation status in premenopausal women with breast cancer. This relationship appears to be more prominent when BRCA1 and BRCA2 mutations are considered separately. We found that women with BRCA2 mutation had significantly higher E 2 levels compared to women without BRCA mutations as well as those with BRCA1 mutations. The E 2 level among women with BRCA2 mutations in this study is much higher than previously reported early follicular phase E 2 level (median: 48 pg/mL, range: 28, 101) among premenopausal breast cancer patients whose BRCA mutation status was not specified [16] . Interestingly, the mean age of BRCA mutation carriers with high basal E 2 level was significantly younger than that of BRCA mutation carriers with low basal E 2 level and non-carriers. Based on these current findings, one may speculate that higher serum E 2 level may be associated with the development of breast cancer in BRCA2 mutation carriers as well as the early-onset of breast cancer in this population.
There are several in vitro and animal studies showing a possible role of BRCA genes in the regulation of E 2 synthesis. It has been previously shown that BRCA1 negatively regulates aromatase action [12] and in turn decreases E 2 synthesis. In mice, it was reported that estrogen biosynthesis by granulosa cells was increased not only in mice carrying a homozygous BRCA1 mutation, but also in heterozygous mutants [17] . Bramley et al. [18] reported that BRCA1/2 haploinsufficiency alters the estrogen sensitivity of normal breast epithelium as assessed by proliferation and induction of estrogen-induced genes. A recent animal study showed that loss of BRCA1 gene function increases murine ovarian epithelial tumor predisposition by increasing estrogen stimulation in the absence of progesterone [19] . Interestingly, in a study with cancer-free women aged 35 years or older, tamoxifen reduced breast cancer incidence among healthy BRCA2 carriers, however, had no effect on cancer incidence among healthy BRCA1 carriers [10] . This finding is consistent with the fact that, in humans, the majority of BRCA1-mutation-related breast cancers are ERa negative, and the majority of BRCA2-mutation-related breast cancers are ERa positive [20] . Our results also support the above studies because women with BRCA2 mutations have higher basal E 2 levels compared to women without BRCA mutations. A prior in vitro investigation shows that estrogen-induced DNA DSBs is ERa dependent [21] . Given that BRCA genes have critical roles in DNA DSBs repair [22, 23] , these previous findings and our finding suggest that BRCA2 mutations may synergistically reduce DNA DSB repair in the presence of higher E 2 and ERa and result in the increased risk of developing breast cancer. In our study, the BRCA mutation carriers with high E 2 levels were significantly younger than BRCA mutation carriers with low E 2 levels and non-carriers. Of note, the mean age of BRCA2 mutation carriers was 32.0 years which tends to be less than that of BRCA1 mutation carriers and non-carriers. These findings may suggest high E 2 levels may be the cause of early-onset breast cancer in BRCA2 mutation carriers. When the foregoing is taken together with the data presented here, it may be worth to design studies to test tamoxifen use at a younger age to reduce breast cancer incidence among BRCA2 mutation carriers.
Although several in vitro and animal studies suggest a possible relationship between BRCA1/2 genes and the regulation of E 2 synthesis [12, [17] [18] [19] , basal E 2 levels were higher only in BRCA2 mutation carriers in this study. It was reported that tissue E 2 levels are selectively elevated in hormone receptor positive breast cancer [24] , and our results show that the prevalence of hormone receptor (ERa and progesterone receptor [PR]) positivity was significantly higher in women with BRCA2 gene mutations. This finding is also consistent with the previous report showing that high serum estrogen level was an independent risk factor of ER (?) breast cancer risk in postmenopausal women [25] . Based on this, it would be interesting to investigate the possible role of the hormone receptor in regulation of serum E 2 levels in BRCA mutation carriers.
Our study has several significant clinical implications. First, this is the first study to show a possible association between BRCA2 gene mutations and serum E 2 levels as well as a potential synergy between the two in breast cancer pathogenesis. Second, it offers a plausible explanation for the development of BRCA2-related tumors in estrogen-sensitive tissues. Third, considering the low prevalence of BRCA gene mutations among general population as well as the difficulty in collecting standardized basal blood samples in an oncology center environment, this is a unique preliminary report generated in the process of fertility preservation evaluation.
There are several limitations in this study. First, the small number of study population does not allow us to make population-level inferences based on our findings. However, we believe that this study provides an appropriate pilot data which would facilitate future larger studies. Second, one might argue about the possibility of bias due to the potential variability of the serum estrogen levels from cycle to cycle and the impact of diagnosis of breast cancer on the hormonal variability. In this study, the potential variability of the serum estrogen levels due to the breast cancer diagnosis was adjusted by collecting all blood samples from those who already developed cancer. Furthermore, the measurements were obtained on menstrual cycle day 2/3 which has been well proven to standardize estradiol measurements in ovarian reserve studies. However, it does not seem to be feasible to control the cycle-to-cycle variability in serum estrogen levels under the time constraint (usually 2-4 weeks between the diagnosis and the initiation of cancer treatments) in this study population. Further research investigating serum estrogen levels from mutation carriers without breast cancer may offer appropriate controls to address this issue.
In this pilot study, we found an association between high basal serum E 2 levels and BRCA2 gene mutations. This is a highly novel and clinically relevant finding since increased baseline E 2 levels can be targeted for risk-screening or prevention of breast carcinogenesis in women with BRCA2 gene mutations. Our data suggest that women who carry BRCA2 mutations may benefit from anti-estrogen treatments. To evaluate the role of E 2 in pathogenesis of breast cancer in BRCA2 mutation carriers, future studies should prospectively determine the association between baseline E 2 levels and the risk of breast cancer development in unaffected BRCA2-mutation carriers. Future studies should also focus on the role of E 2 on the development of BRCA1 mutation-related breast cancers.
